Allogene Therapeutics
David Bonderman is Chairman and Founding Partner of TPG. He holds an undergraduate degree from the University of Washington and graduated from Harvard Law School, where he was a member of the Harvard Law Review and a Sheldon Fellow. David serves on a number of public and private Boards, including China International Capital Corporation Ltd, Cushman & Wakefield, Ryanair Holdings, plc, of which he is Chairman, The Rock and Roll Hall of Fame Foundation, the Grand Canyon Trust, and The Wilderness Society, as well as various academic and advisory boards.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.